Skip to main content

Table 2 Pharmacovigilance mentions in PMI FY 2009 MOPs and in Global Fund Round 8 - Malaria proposals

From: A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals

  PMI FY 2009 Countries (15 total) No. of responses (% of total) Global Fund Round 8 Countries (26 total) No. of responses (% of total)
Country has a Pharmacovigilance Programme mentioned in MOP or Global Fund proposal     
Yes KEN, MDG, MWI, SEN, 4 (27%) BFA, CAF, COL, COM, CIV, ETH, GHA, NGA, PNG, UZB, ZBR, ZWE 12 (46%)
No AGO, ETH, GHA, LBR 4 (27%) AFG, BOL, BRA, COG, ECU, COD, HTI, KGZ, RWA, TJK, TZA, 11 (42%)
Initial Phase of Development BEN, MLI, MOZ, RWA, UGA 5 (33%)   
No mention in proposal TZA, ZMB 2 (13%) IDN, KOR, SWZ, 3 (12%)
Total Respondents   15 (100%)   26 (100%)
A section is dedicated to pharmacovigilance in the MOP or Global Fund proposal     
Yes LBR, MDG, MWI, MLI, MOZ, RWA, SEN, UGA 8 (53%) COL, COM, COG, COD, ETH, GHA, NGA, ZBR 8 (31%)
No AGO, BEN, ETH, GHA, KEN, TZA, ZMB 7 (47%) AFG, BOL, BRA, BFA, CAF, CIV, ECU, HTI, IDN, KOR, KGZ, PNG, RWA, SWZ, TJK, TZA, UZB, ZWE 18 (69%)
Total Respondents   15 (100%)   26 (100%)
A pregnancy registry is mentioned in the MOP or Global Fund proposal     
Yes UGA 1 (7%) None 0 (0%)
No/Not mentioned in proposal AGO, BEN, ETH, GHA, KEN, LBR, MDG, MWI, MLI, MOZ, RWA, SEN, TZA, ZMB 14 (93%) All 26 (100%)
Total Respondents   15 (100%)   26 (100%)
The country requested funds in its MOP or Global Fund proposal for pharmacovigilance activities:     
Yes GHA, MDG, MWI, MLI, MOZ, RWA, UGA 7 (47%) CAF, COL, COG, CIV, NGA, SWZ, ZBR 7 (27%)
No AGO, BEN, ETH, KEN, LBR, SEN, TZA, ZMB 8 (53%) AFG, BOL, BRA, BFA, COM, DR of Congo, ECU, ETH, GHA, HTI, IDN, KOR, KGZ, PNG, RWA, TJK, TZA, UZB, ZWE 19 (73%)
Total Respondents   15 (100%)   26 (100%)
Type of Pharmacovigilance surveillance mentioned in MOP or Global Fund proposal     
Passive only LBR, MWI, UGA 3 (20%) BFA, CAF, COL, COM, COG, CIV, ETH, NGA, PNG, RWA, UZB, ZBR, ZWE 13 (50%)
Active only   0 (0%)   0 (0%)
Both passive and active MDG, MLI, RWA 3 (20%) GHA 1 (4%)
None mentioned AGO, BEN, ETH, GHA, KEN, MOZ, SEN, TZA, ZMB 9 (60%) AFG, BOL, BRA, COD, ECU, HTI, IDN, KOR, KGZ, SWZ, TJK, TZA 12 (46%)
Total Respondents   15 (100%)   26 (100%)
A national agency in charge of Pharmacovigilance activities is mentioned in MOP or Global Fund proposal     
Yes GHA, KEN, LBR, MDG, MWI, MLI, MOZ, RWA, SEN, UGA, ZMB 11 (73%) AFG, BOL, BRA, BFA, CAF, COL, COM, COG, CIV, COD, ETH, GHA, HTI, IDN, KOR, KGZ, NGA, PNG, SWZ, TJK, UZB, ZWE 23 (88%)
No/Not mentioned in proposal AGO, BEN, ETH, TZA 4 (27%) ECU, RWA, TZA 3 (12%)
Total Respondents   15 (100%)   26 (100%)
  1. Afghanistan, AFG; Liberia, LBR; Angola, AGO; Angola, AGO; Madagascar, MDG; Benin, BEN; Malawi, MWI; Bolivia, BOL; Mali, MLI; Brazil, BRA; Mozambique, MOZ; Burkina Faso, BFA; Nigeria, NGA; Central African Republic, CAF; Papua New Guinea, PNG; Colombia, COL; Republic of Congo, COG; Cote D'Ivoire, CIV; Rwanda, RWA; Democratic Republic of Congo, COD; Senegal, SEN; Ecuador, ECU; Swaziland, SWZ; Ethiopia, ETH; Tajikistan, TJK; Ghana, GHA; Tanzania, TZA; Haiti, HTI; Uganda, UGA; Indonesia, IDN; Union of Comoros, COM; Kenya, KEN; Uzbekistan, UZB; Korea, KOR; Zambia, ZMB; Kyrgyzstan, KGZ; Zanzibar, ZBR